1st Department of Propaedeutic Medicine School of Medicine University of Athens Greece

Cancer Sciences Faculty of Medicine University of Southampton UK

Department of Immunology Erasmus MC University Medical Center Rotterdam the Netherlands

Department of Immunology Genetics and Pathology Science for Life Laboratory Uppsala University Sweden

Department of Internal Medicine Hematology and Oncology University Hospital Brno and Faculty of Medicine Masaryk University Brno Czech Republic

Department of Internal Medicine Hematology and Oncology University Hospital Brno and Faculty of Medicine Masaryk University Brno Czech Republic Department of Molecular Medicine CEITEC Central European Institute of Technology Masaryk University Brno Czech Republic

Department of Internal Medicine Hematology and Oncology University Hospital Brno and Faculty of Medicine Masaryk University Brno Czech Republic Department of Molecular Medicine CEITEC Central European Institute of Technology Masaryk University Brno Czech Republic Department of Immunology Genetics and Pathology Science for Life Laboratory Uppsala University Sweden

Department of Laboratory Medicine Stem Cell Center Hematology and Transplantation Lund University Sweden

Department of Medicine Solna Clinical Epidemiology Unit Karolinska Institutet Stockholm Sweden

Department of Molecular Medicine CEITEC Central European Institute of Technology Masaryk University Brno Czech Republic

Department of Molecular Pathology Royal Bournemouth Hospital UK

Division of Experimental Oncology and Department of Onco Hematology IRCCS San Raffaele Scientific Institute Milan Italy

Hematology Department General Hospital of Nikea Piraeus Greece

Institute of Applied Biosciences CERTH Thessaloniki Greece

Institute of Applied Biosciences CERTH Thessaloniki Greece Hematology Department and HCT Unit G Papanicolaou Hospital Thessaloniki Greece

Laboratory of Hematology Hospital Pitie Salpetriere and University Pierre and Marie Curie Paris France

Zobrazit více v PubMed

Sutton L-A, Rosenquist R. The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia. Semin Cancer Biol. 2015;34:22–35. PubMed

Agathangelidis A, Darzentas N, Hadzidimitriou A, et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood. 2012;119(19):4467–4475. PubMed PMC

Baliakas P, Hadzidimitriou A, Sutton L-A, et al. Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study. Lancet Haematol. 2014;1(2):e74–84. PubMed

Stankovic T, Stewart GS, Fegan C, et al. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage. Blood. 2002;99(1):300–309. PubMed

Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–5456. PubMed PMC

Strefford JC, Sutton L-A, Baliakas P, et al. Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2. Leukemia. 2013;27(11):2196–2199. PubMed

Rossi D, Spina V, Bomben R, et al. Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. Blood. 2013;121(24):4902–4905. PubMed

Bendl J, Stourac J, Salanda O, et al. PredictSNP: robust and accurate consensus classifier for prediction of disease-related mutations. PLoS Comput Biol. 2014;10(1):e1003440. PubMed PMC

Roos G, Kröber A, Grabowski P, et al. Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. Blood. 2008;111(4):2246–2252. PubMed

Strefford JC, Kadalayil L, Forster J, et al. Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial. Leukemia. 2015;29(12):2411–2414. PubMed PMC

Lin TT, Letsolo BT, Jones RE, et al. Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis. Blood. 2010;116(11):1899–1907. PubMed

Britt-Compton B, Lin TT, Ahmed G, et al. Extreme telomere erosion in ATM-mutated and 11q-deleted CLL patients is independent of disease stage. Leukemia. 2012;26(4):826–830. PubMed

Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res. 2002;30(10):e47. PubMed PMC

Baliakas P, Agathangelidis A, Hadzidimitriou A, et al. Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. Blood. 2015;125(5):856–859. PubMed PMC

Mansouri L, Grabowski P, Degerman S, et al. Short telomere length is associated with NOTCH1/SF3B1/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients. Am J Hematol. 2013;88(8):647–651. PubMed

The non-canonical BAF chromatin remodeling complex is a novel target of spliceosome dysregulation in SF3B1-mutated chronic lymphocytic leukemia

Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes

Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia

Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations